Ischemic stroke with dizziness in the posterior circulation
Conditions
Interventions
Acupuncture group (experimental group A):Basic treatment: Based on the Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack in 2022, including ? controlling ris
? When there are no contraindications, routine doses of aspirin are administered to prevent platelet aggregation and atorvastatin is used to regulate lipid and stabilize plaques
? Education on diet, lifestyle, and exercise.
Experiment Group A (Acupuncture Group): On the basis of basic treatment, select points Dazhui, Fengchi (bilateral), Wangu (bilateral), and Taichong (bi
Sham acupuncture group (Experiment B group) :Basic treatment: Based on the Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack in 2022, including ? controlling
? Education on diet, lifestyle, and exercise.
Experiment Group B (sham acupuncture group): On the basis of basic treatment, 4 non acupoint points were taken from the neck, shoulder, and lower limbs
Drug control group (Experiment C group):Basic treatment: Based on the Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack in 2022, including ? controlling risk
? Education on diet, lifestyle, and exercise.
Experiment group C (drug control group): Oral adm
Sponsors
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Those who meet the diagnostic criteria of Chinese and Western medicine mentioned above; (2) Gender unlimited, 18 years = Age = 80 years; (3) Dizziness, dizziness, or instability symptoms lasting for = 1 week, with a frequency of = 2 episodes; (4) Those whose vital signs and condition are basically stable; (5) Can complete a dizziness diary; (6) The participants voluntarily participate in this study by signing or having their immediate family members sign an informed consent form (see appendix). Note: Only subjects who meet the above 6 criteria can be included in this study.
Exclusion criteria
Exclusion criteria: (1) Vertigo caused by other diseases and trauma, such as intracranial space occupying, cerebral hemorrhage, and otogenic, metabolic, infectious diseases; (2) Bilateral posterior circulation area infarction, or (and) combined anterior circulation area infarction; (3) Patients with severe primary diseases such as cardiovascular, liver, kidney, digestive, and hematopoietic systems; (4) In the past six months, there have been other central diseases (such as cerebral hemorrhage, Parkinson's disease, intracranial infection, etc.); (5) Patients with severe skin damage or skin diseases in the treated area; (6) Patients with coagulation disorders or hemorrhagic diseases; (7) Pregnant women, lactating women, and women with fertility requirements in the past six months; (8) Unable to understand or record Dizziness Day journalists; (9) Comatose and consciousness impaired patients; (10) Individuals who are unable to complete research due to mental illness, cognitive or emotional disorders; (11) Individuals who are currently or have participated in other clinical trials in the past three months. Note: Participants who meet any of the above criteria should be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| dizziness handicap inventory, DHI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dizziness and Anxiety Rating Scale, DARS;Dizziness frequency and improvement value (compared to baseline period);Duration and improvement value of dizziness (compared to baseline period);VAS score and VAS score improvement value (compared to baseline period);Dizziness affects the degree of life rating;transcranial Doppler, TCD; | — |
Countries
China
Contacts
Public ContactQuan Xie
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Outcome results
None listed